Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Litigation: US DOJ Intensifies Pressure On Sponsors With New Task Force

Executive Summary

Task force will target unlawful marketing by opioid manufacturers, assist state lawsuits, and seek compensation for costs of opioid crisis.

You may also be interested in...



Will US Government Pursue Fewer False Claims Act Cases In 2019?

Fallout from Supreme Court's Escobar decision and Department of Justice memos could impact types of healthcare fraud complaints in which the government intervenes.

Will Opioid Supply Be Slashed? US Attorney General Takes Aim At Aggregate Production Quotas

Looking to reduce opioid prescriptions, Sessions asks DEA to consider revising regulations governing its quotas. President Trump says DOJ may file separate suit against opioid makers.

Opioid Litigation: Court Asks US FDA To Attend Education Session

Judge overseeing multidistrict litigation convenes meeting with senior pharma executives, government plaintiffs and others to learn about supply-chain dynamics and other issues to resolve more than 200 suits.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel